• Silexion Therapeutics priced a USD 2.5 million public offering of 3,846,161 ordinary shares or equivalents with Series E warrants.
• Combined offering price set at USD 0.65 per share or equivalent, including accompanying warrants.
• Series E warrants carry a USD 0.65 exercise price, are exercisable immediately, expire five years from issuance.
• Closing expected on Aug. 13, 2026, subject to customary closing conditions.
• Net proceeds earmarked to advance the SIL204 clinical trial, fund general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608112001PRIMZONEFULLFEED9808324) on August 12, 2026, and is solely responsible for the information contained therein.